Skip to main content

NIA Funding Policy for FY 2017

End-of-Year 2017 NIA Funding Line Policy

The tables below show NIA final funding lines for FY 2017 for the general allocation and for the Alzheimer's allocation. The tables do not show funding lines for initiatives with set-asides. Contact your program officer for information on these applications.

We are paying most eligible applications to the funding lines shown. For individual reasons, a few applications within these lines will not be paid this year. Items changed since the July update are shown in bold.

CSR-reviewed Research Applications:
  General Pay line, <500k General Pay line, => 500k ADRD pay line, <500k ADRD pay line, => 500k
All (except below)
19%
16%
28%
25%
New Investigator R01s and first time renewing
22%
19%
31%
28%
Early Stage Investigator R01s and first time renewing
25%
22%
33%
30%

New investigator: An applicant who has not received a prior R01 award or its equivalent.

Early-Stage Investigator: A new investigator who is within 10 years of finishing research training.

First-time renewing; A former new or early-stage investigator's first renewal application when the investigator has no other NIH grant support.

ADRD: Research on Alzheimer's disease and on Alzheimer's-related Dementias

NIA-reviewed Applications
  General pay line ADRD pay line
Program projects
35
40
Other NIA-reviewed research
34
40
Training-related Applications
  General pay line ADRD pay line
Training grants
22
27
Career awards
22
36
Fellowships
31
40

Other Mechanisms/Activity codes

From our general allocation, we are making initial payments from the August Council round of Small Business SBIR applications to a score of 25 and of STTR applications to a score of 35. We expect to pay additional applications from this August cycle in FY 2018. From our Alzheimer's allocation, we are paying most scored SBIR applications, and paying STTR applications on these topics to a score of 40.

July 2017: NIA Funding Policy Update FY 2017

  1. Following publication of NIH Fiscal Policy for Grant Awards – FY 2017 (NOT-OD-17-086), NIA announces that we are paying non-competing continuation (Type 5) awards at their full previously committed level and will restore to their full committed level those awards previously issued at 90% of their committed level.
  2. The table below shows updated funding lines for CSR-reviewed research grants from the general fund. It also includes funding lines for research on Alzheimer's disease for reference. The lines for Alzheimer's research have not changed from the earlier post in May 2017. Following NIH policy, NIA is now giving advantage in our pay line to first renewal applications from prior early stage and new investigators as well as to initial awards for early-stage and other new investigators. The first renewal advantage is provided only from the general allocation, not from the Alzheimer's allocation.

Funding Lines as of July 2017

CSR-reviewed Research Applications:
  General Pay line, <500k General Pay line, => 500k ADRD pay line, <500k ADRD pay line, => 500k
All (except below)
15%
12%
28%
25%
New Investigator R01s
18%
15%
31%
28%
Early Stage Investigator R01s
25%
22%
33%
30%

New investigator: An applicant who has not received a prior R01 award or its equivalent.

Early-Stage Investigator: A new investigator who is within 10 years of finishing research training.

Bolded percentages indicate a change from the prior-announced line.

ADRD: Research on Alzheimer's disease and on Alzheimer's-related Dementias

Career Award Pay lines

NIA is setting a final pay line in the general allocation for career awards at 22 and at 36 for the Alzheimer's allocation for career awards.

All other funding lines remain as shown in the tables below.

May 2017: NIA Funding Policy Update FY 2017

The National Institute on Aging is making immediate changes to our previously announced funding lines. Once we have received full details on the recently announced budget we will prepare a fuller funding policy statement covering all activity codes and both competing and non-competing awards. The changes below are effective immediately.

We are restoring to full funding those ADRD competing awards, made to date in FY 2017, that we administratively reduced by an average of 18% below requested costs. We will also pay ADRD-related competing awards for the remainder of the fiscal year at full requested costs after adjustment for any recommended cost reductions.

Changes to Funding Lines

CSR-reviewed Research Applications:
  General Pay line, <500k General Pay line, => 500k ADRD pay line, <500k ADRD pay line, => 500k
All (except below)
11%
8%
28%
25%
New Investigator R01s
14%
11%
31%
28%
Early Stage Investigator R01s
16%
13%
33%
30%

New investigator: An applicant who has not received a prior R01 award or its equivalent.

Early-Stage Investigator: A new investigator who is within 10 years of finishing research training.

Bolded percentages indicate a change from the prior-announced line.

ADRD: Research on Alzheimer's disease and on Alzheimer's-related Dementias

Training-related Applications
  General pay line ADRD pay line
Training grants
22
27
Career awards
19
27
Fellowships
26
40

February 2017

The National Institutes of Health are operating under a continuing resolution (CR) first passed on September 29, 2016, and extended on December 9, 2016. The current extension ends on April 28, 2017. NIH is provided funds at a little below the FY 2016 enacted level of support during this CR. NIH policy during the CR is to issue non-competing research grant awards at 90% of the most recent committed level (generally the FY 2016 award). Upward adjustments will be considered after a full year appropriation is enacted.

The National Institute on Aging (NIA) is following NIH policy on noncompeting awards. Guidance on funding lines for competing awards during the CR is provided below.

As a cost management strategy, NIA is continuing its policy of making administrative cuts to most research grants prior to award. The average administrative reduction is set at 18%. This reduction applies both to general research areas and to ADRD research areas. Upward adjustments to research awards on ADRD will be considered after a full year appropriation is enacted. Small grants (R03) and Exploratory/Developmental (R21) awards will be paid without administrative cuts.

CSR-reviewed Research Applications:
  General Pay line, <500k General Pay line, => 500k ADRD pay line, <500k ADRD pay line, => 500k
All (except below)
11%
8%
18%
15%
New Investigator R01s
14%
11%
21%
18%
Early Stage Investigator R01s
16%
13%
23%
20%

ADRD: Research on Alzheimer's disease and Alzheimer's-related dementias

New Investigator: An applicant who has not received a prior R01 award or its equivalent.

Early-Stage Investigator: A new investigator who is within 10 years of finishing research training

NIA-reviewed Applications
  General pay line ADRD pay line
Program projects
28
31
Other NIA-reviewed research
22
30
Training-related Applications
  General pay line ADRD pay line
Training grants (T32, T35)
19
27
Career awards
16
27
Fellowships
26
33

Other Mechanisms/Activity codes

We are paying Small Business Innovation Research (SBIR) R43 and R44 applications through a score of 40. Too few Small Business Technology Transfer applications are submitted to publish a general line. Applicants should contact program officers for information concerning application status for these applications.